Professor Matter can be a pioneer of the world's first targeted cancer therapy, imatinib mesylate, known as Glivec also. His discovery turned chronic myeloid leukaemia from a deadly disease into one that can be treated with an oral pill with almost 90 percent long-term survival rate, with little if any side-effects. Following Glivec's success in CML, it’s been applied to various other malignant cancers successfully. Professor Matter's groundbreaking research demonstrated that by specifically inhibiting the activity of key oncogenic cells, it is possible to counteract cancer in the molecular biology level. Chairman of A*STAR's Biomedical Research Council , Professor Sir George Radda said, ‘This award gives due acknowledgement to Alex's significant work which revolutionised anti-cancer medication development and gave a increase to the fight cancer globally.During this phase, sufficient oxygen is available that requires a dramatic increase in Complex I activity to drive the electron passing through ETC. Another possibility is that DLA imposed effect not on Complex I but on SIRT1 directly, which modulated a range of proteins, including NDUFA10. The cardioprotective role of DLA observed in current study was a collective outcome of the activation of these proteins.Study has demonstrated that SIRT1 mutant mice exhibit notable developmental defects in the heart. Moderate increased SIRT1 was found to protect the heart against oxidative stress by upregulating antioxidant expressions.